I-O / TKI combo shows promise in tough-to-treat cancers

21 September 2020
merck_co_large

Combo therapies featuring an immunotherapy and a tyrosine kinase inhibitor (TKI) are all the rage at this year’s annual congress of the European Society of Medical Oncology (ESMO).

This type of combination has proven effective in a range of cancer indications, including in kidney cancer, with Merck & Co’s (NYSE: MRK) superstar checkpoint blocker Keytruda (pembrolizumab) attracting the most attention.

This year Merck is facing competition in that indication, as well as in gastric cancer, where Keytruda has been paired with a unique oral TKI, Lenvima (lenvatinib), from Japan’s Eisai (TYO: 4523), in the LEAP studies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology